Close Menu

Personalis

The company is offering around 7.9 million shares of common stock at a price of $17 per share and is granting the underwriters an option to buy an additional 1.2 million shares.

The company expects to offer 6.7 million common shares at a maximum offering price of $16 per share.

FLX Bio will apply Personalis' ImmunoID Next platform as part of a Phase I/II clinical trial evaluating its FLX475 drug in cancer therapy.

The ACE ImmunoID test uses exome and transcriptome sequencing to identify neoantigens for the development of personalized cancer vaccines.

The contract was awarded as part of the VA's Precision Oncology Program, which aims to provide advanced clinical care and generate cancer biomarker data.

The company, which first signed on to provide services to the VA's Million Veteran Program in 2013, will provide the department with 34,000 more genomes.

The firm has received approval for two unspecified clinical tests, with a permit under the molecular genetic testing category.

Researchers compared three open source annotation tools, and also looked at correspondence with public databases, identifying a number of stumbling blocks.

The companies will use Personalis' ACE ImmunoID next-generation sequencing platform to analyze tumor samples from clinical trials of Argos' drug.

The company has been working with the VA since 2013, when it it received a contract to provide sequencing and data analysis for enrollees in the Million Veteran Program.

Pages

New US Department of Commerce rules will affect supercomputing in China, according to the Wall Street Journal.

A new analysis finds that it will be more than a century until female computer scientists publish at the same rate as their male counterparts, ScienceInsider reports.

Broad Institute researchers describe an approach they've dubbed "DNA microscopy."

In PLOS this week: epigenetic changes following hepatitis C virus treatment, metagenomic analysis of Ugandan children with febrile illness, and more.